Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Osimertinib
Related studies linked through entity extraction aliases.
A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.
- Status
- COMPLETED
- Phase
- EARLY_PHASE1
18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent Glioblastoma
- Status
- COMPLETED
- Phase
- PHASE2
Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Osimertinib In EGFR Mutant Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Combination of Osimertinib and Aspirin to Treat 1st Generation EGFR-TKI Resistance in NSCLC
- Status
- COMPLETED
- Phase
- PHASE2
Osimertinib With Stereotactic Radiosurgery (SRS) in Brain Metastases From EGFR Positive NSCLC
- Status
- COMPLETED
- Phase
- PHASE1
Combination of Osimertinib and Aspirin to Treat Osimertinib Resistance Non-small Cell Lung Cancer ( NSCLC)
- Status
- UNKNOWN
- Phase
- N/A
A Randomised Phase II Trial of Osimertinib With or Without SRS for EGFR Mutated NSCLC With Brain Metastases
- Status
- COMPLETED
- Phase
- PHASE2
Open-label PET Study With [11C]Osimertinib in Patients With EGFRm NSCLC and Brain Metastases
- Status
- COMPLETED
- Phase
- PHASE1
G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations
- Status
- COMPLETED
- Phase
- PHASE2
Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Osimertinib, Surgery, and Radiation Therapy in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer With EGFR Mutations, NORTHSTAR Study
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
TAGRISSO (Osimertinib) in NSCLC Patients in Whom T790 Mutations Are Detected by Liquid Biopsy
- Status
- COMPLETED
- Phase
- PHASE2
A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Afatinib Osimertinib Sequencing NIS
- Status
- COMPLETED
- Phase
- N/A
DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
- Status
- TERMINATED
- Phase
- PHASE1